Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung.
The continuous emergence of severe acute respiratory coronavirus 2 (SARS-CoV-2) variants and the increasing number of breakthrough infection cases among vaccinated people support the urgent need for research and development of antiviral drugs. Viral entry is an intriguing target for antiviral drug development. We found that diltiazem, a blocker of ... the L-type calcium channel Cav1.2 pore-forming subunit (Cav1.2 ?1c) and an FDA-approved drug, inhibits the binding and internalization of SARS-CoV-2, and decreases SARS-CoV-2 infection in cells and mouse lung. Cav1.2 ?1c interacts with SARS-CoV-2 spike protein and ACE2, and affects the attachment and internalization of SARS-CoV-2. Our finding suggests that diltiazem has potential as a drug against SARS-CoV-2 infection and that Cav1.2 ?1c is a promising target for antiviral drug development for COVID-19.
Mesh Terms:
A549 Cells, Animals, COVID-19, COVID-19 Drug Treatment, Cells, Cultured, Chlorocebus aethiops, Diltiazem, Disease Models, Animal, Female, HEK293 Cells, HeLa Cells, Humans, Lung, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, SARS-CoV-2, Vero Cells, Virus Attachment, Virus Internalization
A549 Cells, Animals, COVID-19, COVID-19 Drug Treatment, Cells, Cultured, Chlorocebus aethiops, Diltiazem, Disease Models, Animal, Female, HEK293 Cells, HeLa Cells, Humans, Lung, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, SARS-CoV-2, Vero Cells, Virus Attachment, Virus Internalization
PLoS Pathog
Date: Feb. 01, 2022
PubMed ID: 35176124
View in: Pubmed Google Scholar
Download Curated Data For This Publication
247429
Switch View:
- Interactions 5